|

CD123/CD33 CART Clinical Trials

1 actively recruiting trial

Also known as: EB-BH2025

Pipeline

Phase 1/2: 1

Top Sponsors

  • Essen Biotech1

Indications

  • Aml1
  • AML, Adult Recurrent1
  • AML, Adult1
  • Acute Myeloid Leukemia1
  • Cancer1

Other1 trial

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.